Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Distinct mobilization of leukocytes and hematopoietic stem cells by CXCR4 peptide antagonist LY2510924 and monoclonal antibody LY2624587.

Peng SB, Van Horn RD, Yin T, Brown RM, Roell WC, Obungu VH, Ruegg C, Wroblewski VJ, Raddad E, Stille JR.

Oncotarget. 2017 Oct 10;8(55):94619-94634. doi: 10.18632/oncotarget.21816. eCollection 2017 Nov 7.

2.

Tumor Trp53 status and genotype affect the bone marrow microenvironment in acute myeloid leukemia.

Jacamo R, Davis RE, Ling X, Sonnylal S, Wang Z, Ma W, Zhang M, Ruvolo P, Ruvolo V, Wang RY, McQueen T, Lowe S, Zuber J, Kornblau SM, Konopleva M, Andreeff M.

Oncotarget. 2017 Jul 6;8(48):83354-83369. doi: 10.18632/oncotarget.19042. eCollection 2017 Oct 13.

3.

The osteoblastic niche in hematopoiesis and hematological myeloid malignancies.

Galán-Díez M, Kousteni S.

Curr Mol Biol Rep. 2017 Jun;3(2):53-62. doi: 10.1007/s40610-017-0055-9. Epub 2017 May 2.

PMID:
29098141
4.

Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia.

Webster JA, Tibes R, Morris L, Blackford AL, Litzow M, Patnaik M, Rosner GL, Gojo I, Kinders R, Wang L, Doyle LA, Huntoon CJ, Karnitz LM, Kaufmann SH, Karp JE, Smith BD.

Leuk Res. 2017 Oct;61:108-116. doi: 10.1016/j.leukres.2017.09.005. Epub 2017 Sep 20.

PMID:
28957699
5.

Inhibition of CXCL12/CXCR4 axis as a potential targeted therapy of advanced gastric carcinoma.

Xue LJ, Mao XB, Ren LL, Chu XY.

Cancer Med. 2017 Jun;6(6):1424-1436. doi: 10.1002/cam4.1085. Epub 2017 May 23. Review.

6.

CXCR4 knockdown inhibits the growth and invasion of nasopharyngeal cancer stem cells.

Tian Y, Song Y, Bai W, Ma X, Ren Z.

Oncol Lett. 2017 Apr;13(4):2253-2259. doi: 10.3892/ol.2017.5694. Epub 2017 Feb 8.

7.

A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia.

Uy GL, Rettig MP, Stone RM, Konopleva MY, Andreeff M, McFarland K, Shannon W, Fletcher TR, Reineck T, Eades W, Stockerl-Goldstein K, Abboud CN, Jacoby MA, Westervelt P, DiPersio JF.

Blood Cancer J. 2017 Mar 10;7(3):e542. doi: 10.1038/bcj.2017.21. No abstract available.

8.

Focal Adhesion Kinase as a Potential Target in AML and MDS.

Carter BZ, Mak PY, Wang X, Yang H, Garcia-Manero G, Mak DH, Mu H, Ruvolo VR, Qiu Y, Coombes K, Zhang N, Ragon B, Weaver DT, Pachter JA, Kornblau S, Andreeff M.

Mol Cancer Ther. 2017 Jun;16(6):1133-1144. doi: 10.1158/1535-7163.MCT-16-0719. Epub 2017 Mar 7.

PMID:
28270436
9.

Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside.

Cho BS, Kim HJ, Konopleva M.

Korean J Intern Med. 2017 Mar;32(2):248-257. doi: 10.3904/kjim.2016.244. Epub 2017 Feb 21. Review.

10.

Resistance of leukemia cells to cytarabine chemotherapy is mediated by bone marrow stroma, involves cell-surface equilibrative nucleoside transporter-1 removal and correlates with patient outcome.

Macanas-Pirard P, Broekhuizen R, González A, Oyanadel C, Ernst D, García P, Montecinos VP, Court F, Ocqueteau M, Ramirez P, Nervi B.

Oncotarget. 2017 Apr 4;8(14):23073-23086. doi: 10.18632/oncotarget.14981.

11.

Understanding of leukemic stem cells and their clinical implications.

Wang X, Huang S, Chen JL.

Mol Cancer. 2017 Jan 30;16(1):2. doi: 10.1186/s12943-016-0574-7. Review.

12.

Mesenchymal stromal cells in myeloid malignancies.

Schroeder T, Geyh S, Germing U, Haas R.

Blood Res. 2016 Dec;51(4):225-232. doi: 10.5045/br.2016.51.4.225. Epub 2016 Dec 23. Review.

13.

Myeloid malignancies and the microenvironment.

Korn C, Méndez-Ferrer S.

Blood. 2017 Feb 16;129(7):811-822. doi: 10.1182/blood-2016-09-670224. Epub 2016 Nov 15.

14.

The CCL2/CCR2 Axis Affects Transmigration and Proliferation but Not Resistance to Chemotherapy of Acute Myeloid Leukemia Cells.

Macanas-Pirard P, Quezada T, Navarrete L, Broekhuizen R, Leisewitz A, Nervi B, Ramírez PA.

PLoS One. 2017 Jan 3;12(1):e0168888. doi: 10.1371/journal.pone.0168888. eCollection 2017.

15.

Sphingosine-1-Phosphate Receptor-3 Supports Hematopoietic Stem and Progenitor Cell Residence Within the Bone Marrow Niche.

Ogle ME, Olingy CE, Awojoodu AO, Das A, Ortiz RA, Cheung HY, Botchwey EA.

Stem Cells. 2017 Apr;35(4):1040-1052. doi: 10.1002/stem.2556. Epub 2017 Jan 19.

PMID:
28026131
16.

Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-κB inhibition in acute myeloid leukemia (AML).

Omsland M, Bruserud Ø, Gjertsen BT, Andresen V.

Oncotarget. 2017 Jan 31;8(5):7946-7963. doi: 10.18632/oncotarget.13853.

17.

Mesenchymal Stromal Cells Can Regulate the Immune Response in the Tumor Microenvironment.

Poggi A, Giuliani M.

Vaccines (Basel). 2016 Nov 8;4(4). pii: E41. Review.

18.

Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities.

Stahl M, Kim TK, Zeidan AM.

World J Stem Cells. 2016 Oct 26;8(10):316-331. Review.

19.

Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.

Lonetti A, Cappellini A, Bertaina A, Locatelli F, Pession A, Buontempo F, Evangelisti C, Evangelisti C, Orsini E, Zambonin L, Neri LM, Martelli AM, Chiarini F.

J Hematol Oncol. 2016 Oct 24;9(1):114.

20.

Translating leukemia stem cells into the clinical setting: Harmonizing the heterogeneity.

Yanagisawa B, Ghiaur G, Smith BD, Jones RJ.

Exp Hematol. 2016 Dec;44(12):1130-1137. doi: 10.1016/j.exphem.2016.08.010. Epub 2016 Sep 28. Review.

Supplemental Content

Support Center